JP2006502143A - 向代謝型グルタミン酸受容体のアセトフェノン増強因子 - Google Patents

向代謝型グルタミン酸受容体のアセトフェノン増強因子 Download PDF

Info

Publication number
JP2006502143A
JP2006502143A JP2004529871A JP2004529871A JP2006502143A JP 2006502143 A JP2006502143 A JP 2006502143A JP 2004529871 A JP2004529871 A JP 2004529871A JP 2004529871 A JP2004529871 A JP 2004529871A JP 2006502143 A JP2006502143 A JP 2006502143A
Authority
JP
Japan
Prior art keywords
compound
phenyl
mmol
alkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004529871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502143A5 (2
Inventor
キユーブ，ロウイーナ・ブイ
ピンカートン，アンソニー・ビー
バーニア，ジーン−ミシエル
チヤオ，シオウミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2006502143A publication Critical patent/JP2006502143A/ja
Publication of JP2006502143A5 publication Critical patent/JP2006502143A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004529871A 2002-08-26 2003-08-22 向代謝型グルタミン酸受容体のアセトフェノン増強因子 Withdrawn JP2006502143A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40590802P 2002-08-26 2002-08-26
PCT/US2003/026377 WO2004018386A2 (en) 2002-08-26 2003-08-22 Acetophenone potentiators of metabotropic glutamate receptors

Publications (2)

Publication Number Publication Date
JP2006502143A true JP2006502143A (ja) 2006-01-19
JP2006502143A5 JP2006502143A5 (2) 2006-10-05

Family

ID=31946942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004529871A Withdrawn JP2006502143A (ja) 2002-08-26 2003-08-22 向代謝型グルタミン酸受容体のアセトフェノン増強因子

Country Status (6)

Country Link
US (1) US20050288346A1 (2)
EP (1) EP1556038A2 (2)
JP (1) JP2006502143A (2)
AU (1) AU2003262805A1 (2)
CA (1) CA2495756A1 (2)
WO (1) WO2004018386A2 (2)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520680A (ja) * 2004-11-22 2008-06-19 イーライ リリー アンド カンパニー グルタミン酸受容体の増強剤
JP2010520263A (ja) * 2007-03-07 2010-06-10 オルソ−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド ３−シアノ−４−（４−フェニル−ピペリジン−１−イル）−ピリジン−２−オン誘導体
JP2010520265A (ja) * 2007-03-07 2010-06-10 オルソ−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド ３−シアノ−４−（４−テトラヒドロピラン−フェニル）−ピリジン−２−オン誘導体
JP2010520264A (ja) * 2007-03-07 2010-06-10 オルソ−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド １，４−ジ置換３−シアノピリドン誘導体とそれらのポジティブｍＧｌｕＲ２−受容体モジュレーター
JP2010539120A (ja) * 2007-09-14 2010-12-16 オルソー−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554696C (en) 2004-02-13 2009-06-30 Warner-Lambert Company Llc Androgen receptor modulators
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
JP2007533726A (ja) * 2004-04-22 2007-11-22 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレーター
MXPA06015169A (es) 2004-07-08 2007-08-21 Warner Lambert Co Moduladores de androgenos.
CA2574956A1 (en) * 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2011226942B2 (en) * 2004-11-22 2012-06-28 Eli Lilly And Company Potentiators of glutamate receptors
CA2598531A1 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
TW201006801A (en) * 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
EP3129345B1 (en) * 2014-04-06 2023-03-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
AU2019406825A1 (en) * 2018-12-17 2021-07-15 6th Wave Innovations Corp. Lithium extraction with crown ethers
WO2023122276A1 (en) * 2021-12-23 2023-06-29 Sanford Burnham Prebys Medical Discovery Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
EP4299124A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 nanobodies for use as biomolecule transporter

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2058785B (en) * 1979-09-05 1983-05-25 Glaxo Group Ltd Phenol derivatives
DE3116079A1 (de) * 1981-04-23 1982-11-11 Robert Bosch Gmbh, 7000 Stuttgart Pruefsystem
US4567201A (en) * 1981-11-25 1986-01-28 Takeda Chemical Industries, Ltd. Diphenoxypropane derivatives and compositions of antiasthmatic and antiinflammatory agents thereof
ES8505199A1 (es) * 1982-10-21 1985-05-16 Lilly Industries Ltd Un procedimiento para la preparacion de derivados de difenilalquilenicos.
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
GB8318889D0 (en) * 1983-07-13 1983-08-17 Lilly Industries Ltd Pharmaceutical compounds
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520680A (ja) * 2004-11-22 2008-06-19 イーライ リリー アンド カンパニー グルタミン酸受容体の増強剤
JP2008520676A (ja) * 2004-11-22 2008-06-19 イーライ リリー アンド カンパニー グルタミン酸受容体の増強剤
JP2010520263A (ja) * 2007-03-07 2010-06-10 オルソ−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド ３−シアノ−４−（４−フェニル−ピペリジン−１−イル）−ピリジン−２−オン誘導体
JP2010520265A (ja) * 2007-03-07 2010-06-10 オルソ−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド ３−シアノ−４−（４−テトラヒドロピラン−フェニル）−ピリジン−２−オン誘導体
JP2010520264A (ja) * 2007-03-07 2010-06-10 オルソ−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド １，４−ジ置換３−シアノピリドン誘導体とそれらのポジティブｍＧｌｕＲ２−受容体モジュレーター
JP2010539120A (ja) * 2007-09-14 2010-12-16 オルソー−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン

Also Published As

Publication number Publication date
CA2495756A1 (en) 2004-03-04
WO2004018386A2 (en) 2004-03-04
EP1556038A2 (en) 2005-07-27
WO2004018386A3 (en) 2004-11-25
AU2003262805A1 (en) 2004-03-11
US20050288346A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
JP2006502143A (ja) 向代謝型グルタミン酸受容体のアセトフェノン増強因子
US7960417B2 (en) Benzazole potentiators of metabotropic glutamate receptors
JP2008517920A (ja) 代謝調節型グルタミン酸受容体の複素環式インダノン増強因子
JP2008508288A (ja) 代謝調節型グルタミン酸受容体のヘテロ環式アセトフェノン増強剤
JP2008508306A (ja) メタボトロピックグルタミン酸受容体のインダノン増強剤
JP2008518913A (ja) 代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子
US7507836B2 (en) Benzamide modulators of metabotropic glutamate receptors
JP2011520892A (ja) オキサゾロベンゾイミダゾール誘導体
BG100487A (bg) 3-(5-тетразолил-бензил)амино-пиперидинови производни, методи за получаването им и фармацевтични състави с тях, използувани както при метод за лечение, така и за производство на лекарства с приложениепри лечение на състояния, в които са посредници тахикинините
JP2011510083A (ja) ３，５−二置換−１，３−オキサゾリジン−２−オン誘導体
JP2005506292A5 (2)
JP2012503658A (ja) オキサゾロベンゾイミダゾール誘導体
RS50210B (sr) Derivati (1-fenaci-3-fenil-3-piperidiletil) piperidina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
CN103339107A (zh) 作为鞘氨醇1-磷酸(s1p)受体调节剂的新型氮杂环丁烷衍生物
CN101426786A (zh) 代谢型谷氨酸受体吲哚增强剂
CN120865048A (zh) Mas相关g蛋白受体x4调节剂及用途

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060821

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080626